Dear Editor,In the United States, pancreatic cancer is considered the fourth most common reason for cancer-related deaths; over 53% of patients are diagnosed at end-stage with a 5year survival rate of less than 3% [1]. Incomplete removal of all cancerous cells generally leads to local recurrence of pancreatic cancer [2]. Thus, the detection of tumor margin status plays an essential role in the complete resection of pancreatic cancer. Most of the existing imaging modalities, like computed tomography and magnetic resonance imaging, are primarily used for preoperative planning; these modalities also have issues of bulky equipment, radiation concerns, and slow imaging speed [2]. Thus, these modalities can neither provide an intraoperative diagnosis of cancer with high sensitivity and specificity nor be used to define tumor margins [3].Indocyanine green (ICG), a clinically approved fluorescent dye, has become a popular choice in various clinical applications, e.g., dental imaging [4,5]. Many studies suggested that ICG could become an ideal fluorescent agent to enhance the imaging contrast between normal tissues and certain tumors, such as breast cancer, gastric cancer, head and neck cancer, and pancreatic tumor [6]. However, most of the existing studies using ICG performed the imaging in the first near-infrared window (NIR-I, 700-1000 nm) [6]. Compared to traditional NIR-I, imaging in the second NIR window (NIR-II, 1000-1700 nm) could achieve a deeper tissue penetration depth and acquire good imaging quality because of its low autofluorescence and photon scattering[7], especially with ICG [8]. Existing studies reported ICG-assisted NIR fluorescence imaging in NIR-II (ICG-NIRF-II) for the detection of thoracic malignancy[9] and